Evidence map›Paper›PMID 41439997›Full record

ArticleCells2025

Lactose-Modified Hyaluronic Acid Molecule Attenuates In Vitro Chondrocyte Inflammation.

Alice Cristina Donato, Elisa Belluzzi, Valentina Masola, Pietro Ruggieri, Paola Brun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alice Cristina DonatoHistology Unit, Department of Molecular Medicine (DMM), University of Padova, 35121 Padova, Italy.
Elisa BelluzziMusculoskeletal Pathology and Oncology Laboratory, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Via Giustiniani 3, 35128 Padova, Italy.ORCID 0000-0003-1129-2574
Valentina MasolaDepartment of Biomedical Sciences (DBS), University of Padova, 35121 Padova, Italy.ORCID 0000-0003-2341-2481
Pietro RuggieriOrthopedics and Orthopedic Oncology, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University Hospital of Padova, Via Giustiniani 3, 35128 Padova, Italy.ORCID 0000-0001-9617-9882
Paola BrunHistology Unit, Department of Molecular Medicine (DMM), University of Padova, 35121 Padova, Italy.ORCID 0000-0002-4204-3549

Funding

GlycoCore Pharma s.r.l. (Como, Italy) 00
6 · The paper itself

Abstract

backgroundOsteoarthritis (OA) is a chronic degenerative whole joint disease characterized by cartilage breakdown and inflammation. Galectin-3 (Gal-3), a β-galactoside-binding lectin secreted into the extracellular space, binds to glycosylated components of the extracellular matrix (ECM), modulating cell-matrix interactions and inflammation. This study aims to evaluate the anti-inflammatory effects of Hylach

methodsChondrocyte viability, after both Hylach

resultsHA and Hylach

conclusionsHylach

Indexed as

ChondrocytesHyaluronic AcidInflammationLactoseCells, CulturedCell SurvivalGalectin 3HumansInterleukin-1betaOsteoarthritisU937 CellsGalectin 3Hyaluronic AcidInterleukin-1betaLactoseGalectin-3hyaluronic acidHylachinflammationOsteoarthritis

Identifiers

PMID41439997
PMCPMC12731145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.